Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials

Abstract

Background: Nervous and muscular adverse events (NMAEs) have garnered considerable attention after the vaccination against coronavirus disease (COVID-19). However, the incidences of NMAEs remain unclear. We aimed to calculate the pooled event rate of NMAEs after COVID-19 vaccination. Methods: A systematic review and meta-analysis of clinical trials on the incidences of NMAEs after COVID-19 vaccination was conducted. The PubMed, Medline, Embase, Cochrane Library, and Chinese National Knowledge Infrastructure databases were searched from inception to 2 June 2021. Two independent reviewers selected the study and extracted the data. Categorical variables were analyzed using Pearson’s chi-square test. The pooled odds ratio (OR) with the corresponding 95% confidence intervals (CIs) were estimated and generated with random or fixed effects models. The protocol of the present study was registered on PROSPERO (CRD42021240450). Results: In 15 phase 1/2 trials, NMAEs occurred in 29.2% vs. 21.6% (p < 0.001) vaccinated participants and controls. Headache and myalgia accounted for 98.2% and 97.7%, and their incidences were 16.4% vs. 13.9% (OR = 1.97, 95% CI = 1.28–3.06, p = 0.002) and 16.0% vs. 7.9% (OR = 3.31, 95% CI = 2.05–5.35, p < 0.001) in the vaccine and control groups, respectively. Headache and myalgia were more frequent in the newly licensed vaccines (OR = 1.97, 95% CI = 1.28–3.06, p = 0.02 and OR = 3.31, 95% CI = 2.05–5.35, p < 0.001) and younger adults (OR = 1.40, 95% CI = 1.12–1.75, p = 0.003 and OR = 1.54, 95% CI = 1.20–1.96, p < 0.001). In four open-label trials, the incidences of headache, myalgia, and unsolicited NMAEs were 38.7%, 27.4%, and 1.5%. Following vaccination in phase 3 trials, headache and myalgia were still common with a rate of 29.5% and 19.2%, although the unsolicited NMAEs with incidence rates of ≤ 0.7% were not different from the control group in each study. Conclusions: Following the vaccination, NMAEs are common of which headache and myalgia comprised a considerable measure, although life-threatening unsolicited events are rare. NMAEs should be continuously monitored during the ongoing global COVID-19 vaccination program.

Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials

“…With the starting vaccination, several studies were carried out to ascertain the safety of these vaccines, since they were produced in record time. 20–22 Currently, one systematic review about the thematic showed that of 11 published clinical trials of COVID-19 vaccines included in the study, adverse reactions reported were considered mild to moderate with few severe reactions which were unrelated to the test vaccine. Common adverse events were pain at the site of injection, fever, myalgia, fatigue and headache.…”

Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review

“…The incidence of NMAEs was 29.2% in the vaccine group and 21.6% in the control group, in a total of 15 randomized blinded controlled clinical trials. Systemic neurological symptoms included migraine, dizziness, vertigo, and syncope ( 5 ).…”

A temporal association between COVID‐19 vaccination and immune‐mediated necrotizing myopathy

“…Tsun-Haw Toh MRCP 1 Yen-Fa Toh MPath 2 Kum-Thong Wong FRCPath 2 Nortina Shahrizaila FRCP 1 Khean-Jin Goh FRCP 1 1…”

“…We read with great interest the study of Pham Nguyen et al on the potential of macrolides and fluoroquinolones to worsen myasthenia. 1 We were surprised by the low and insignificant odds ratios (ORs) for myasthenia worsening for fluoroquinolones and macrolides in comparison to beta lactam antibiotics. This is in contrast to a recent result from pharmacovigilance data from the World Health Organization (WHO)…”

“…The recalculated RORs (with all beta lactams as a reference) from Table 1 in the previously published paper 2 were as high as 7.9 (macrolides) and 6.8 (fluoroquinolones), respectively. We can think of two mechanisms that could result in this difference: First, one of the strengths of the study Pham Nguyen et al, 1 as compared to that of Trillenberg and Thern, 2 is that simultaneous prescription of the two target drugs was known and could be handled by mixed effects parametric survival regression. In the framework of VigiBase, with limited knowledge of individual cases, odd ratios would be calculated from the observed frequencies only.…”